Existing vaccines effective against severe Omicron, study suggests
Cellular immunity elicited by the BioNTech/Pfizer and Johnson & Johnson Covid-19 vaccines is effective against the Omicron coronavirus variant, according to a study, suggesting vaccines will protect against severe disease even if the antibody responses against the strain are not as strong or durable.
一项研究表明，由BioNTech/辉瑞(Pfizer)和强生(Johnson & Johnson)新冠疫苗引发的细胞免疫对Omicron变种有效，这似乎表明现有疫苗能够预防重症——即便针对该病毒株的抗体反应不那么强烈或持久。
The findings, contained in a new Harvard medical school study, add to evidence that the current vaccines hold up against severe Covid outcomes, and could help health authorities to decide whether to switch to Omicron-targeted jabs.
哈佛医学院(Harvard Medical School)的这项新研究结果带来更多证据，证明现有疫苗能够预防新冠重症，并且可能有助于卫生当局决定是否改用Omicron靶向疫苗。
“These data suggest that current vaccines may provide considerable protection against severe disease with the Sars-Cov-2 Omicron variant despite the substantial reduction of neutralising antibody responses,” the researchers wrote in the study made public on Monday. The paper has not been peer-reviewed yet.